Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Quarterly Earnings Results, Misses Estimates By $0.36 EPS

Supernus Pharmaceuticals (NASDAQ:SUPN) issued its quarterly earnings data on Tuesday. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.36), Zacks reports. The business had revenue of $170.00 million during the quarter, compared to analysts’ expectations of $175.82 million. Supernus Pharmaceuticals had a return on equity of 14.22% and a net margin of 9.70%.The company’s revenue was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.69 earnings per share. Supernus Pharmaceuticals updated its FY 2025 guidance to EPS.

Supernus Pharmaceuticals Stock Up 0.3%

Supernus Pharmaceuticals stock traded up $0.15 during midday trading on Thursday, reaching $47.26. The company’s stock had a trading volume of 1,441,745 shares, compared to its average volume of 686,743. Supernus Pharmaceuticals has a fifty-two week low of $29.16 and a fifty-two week high of $57.65. The company has a market cap of $2.65 billion, a P/E ratio of 41.10 and a beta of 0.75. The business has a 50-day simple moving average of $48.54 and a 200-day simple moving average of $39.30.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 5,000 shares of the firm’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $45.87, for a total value of $229,350.00. Following the sale, the senior vice president directly owned 15,496 shares in the company, valued at $710,801.52. This trade represents a 24.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jack A. Khattar sold 59,900 shares of the firm’s stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $50.57, for a total value of $3,029,143.00. Following the completion of the sale, the chief executive officer owned 1,206,578 shares in the company, valued at approximately $61,016,649.46. This represents a 4.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 222,741 shares of company stock worth $10,507,792 over the last ninety days. Corporate insiders own 8.80% of the company’s stock.

Institutional Trading of Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Osaic Holdings Inc. increased its position in shares of Supernus Pharmaceuticals by 211.5% during the second quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company’s stock worth $63,000 after purchasing an additional 1,328 shares in the last quarter. Thrivent Financial for Lutherans increased its position in shares of Supernus Pharmaceuticals by 1.5% during the second quarter. Thrivent Financial for Lutherans now owns 41,170 shares of the specialty pharmaceutical company’s stock worth $1,298,000 after purchasing an additional 611 shares in the last quarter. Public Sector Pension Investment Board increased its position in shares of Supernus Pharmaceuticals by 0.3% during the second quarter. Public Sector Pension Investment Board now owns 220,304 shares of the specialty pharmaceutical company’s stock worth $6,944,000 after purchasing an additional 573 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its position in shares of Supernus Pharmaceuticals by 5.7% during the second quarter. CANADA LIFE ASSURANCE Co now owns 61,936 shares of the specialty pharmaceutical company’s stock worth $1,954,000 after purchasing an additional 3,336 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Supernus Pharmaceuticals by 255.5% during the second quarter. Tower Research Capital LLC TRC now owns 4,245 shares of the specialty pharmaceutical company’s stock worth $134,000 after purchasing an additional 3,051 shares in the last quarter.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on SUPN. TD Cowen increased their price objective on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Cantor Fitzgerald raised their price target on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 30th. Wall Street Zen lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Zacks Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $63.25.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.